

hVEGFA/hPD-1/hPD-L1

品系全名	C57BL/6JSmc- <i>Vegfa</i> ^{tm1(hVEGFA)} <i>Pdcd1</i> ^{tm1(hPDCD1)} Cd274tm1(hPD-L1)Smoc
目录号	NM-XA-242143
品系状态	活体

基因信息

品系描述

The hPD-1/hPD-L1(NM-HU-00100) was crossed with hVEGFA(NM-HU-2000028) to generate hVEGFA/hPD-1/hPD-L1 mice.

*使用本品系发表的文献需注明: hVEGFA/hPD-1/hPD-L1 mice (Cat. NO. NM-XA-242143) were purchased from Shanghai Model Organisms Center, Inc..

验证数据




Fig.1 Body weight were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (n=8). (A) Body weight. (B) Body weight change.




Fig.2 Tumor volume were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice. (A) Tumor volume. (B) Relative tumor volume.

MC38-hVEGFA (1×10⁶) were inoculated subcutaneously into hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (male, 8-week-old, n=8).




Fig.3 *In vivo* efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Detection of human VEGFA expression in MC38-hVEGFA/hPD-L1 tumor by ELISA (n=2).




Fig.4 *In vivo* efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Detection of human PD-L1 expression in MC38-hVEGFA/hPD-L1 tumor by FACS (n=2).




Fig.5 *In vivo* efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Body weight were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (female, 13-week-old, n=8). (A) Body weight. (B) Body weight change.




Fig.6 *In vivo* efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Tumor volume were measured twice a week of hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice. MC38-hVEGFA/hPD-L1 (1×10^6) were inoculated subcutaneously into hVEGFA/hPD-1/hPD-L1 (C57BL/6) mice (female, 13-week-old, n=8). (A) Tumor volume. (B) Relative tumor volume.




Fig.7 *In vivo* efficacy assessment of Ivonescimab in hVEGFA/hPD-1/hPD-L1 (C57BL/6) (NM-XA-242143) mice bearing MC38-hVEGFA/hPD-L1 syngeneic tumor.

Flow cytometry analysis of tumor-infiltrating lymphocytes (TILs) from MC38-hVEGFA/hPD-L1 tumor by FACS. Tumor-infiltrating lymphocytes (TILs) were collected to carry out an immunophenotypic analysis by flow cytometry (n=4). According to flow cytometric analysis, post-treatment led to a significant increase in the proportion of T cells, and a substantial reduction in the proportion of myeloid cells.
